Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cometriq cabozantinib: Phase II data

Data from 23 evaluable patients with uveal melanoma in the cohort of patients with melanoma in a double-blind, open-label, international Phase II trial showed that once-daily 100 mg cabozantinib led to a median PFS of 4.8 months and an

Read the full 397 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers